Invests in
Sectors:
Min Investment:
$10,000,000.00Max Investment:
$50,000,000.00Target Investment:
$25,000,000.00
Skills
Education
- high school
- high school
Lists including Samantha
Work Experience
Board Member, Chair of Nom & Gov Committee
2024
2022
Board Member, Chair of Compensation Committee
2022
2021 - 2024
Chief Executive Officer
2021 - 2024
2018 - 2022
Member of the Board; Chair of Audit Committee
2018 - 2022
Inspired by nature, HotSpot Therapeutics is moving beyond active site inhibition to allosterically target drivers of protein function and deliver first-in-class medicines with exceptional properties.
2018 - 2021
CEO
2018 - 2021
Quench Bio sought to discover inhibitors of gasdermin, a novel target that plays a key role in inflammatory cell death. We aimed to provide effective therapies for patients with severe inflammatory diseases. Quench Bio raised a $50M Series A funded by Atlas Venture, RA Capital, Arix Bioscience and AbbVie Ventures. After almost 3 years of attempts to drug this interesting target, we wound down Quench and returned capital to the investors.
2016 - 2017
COO and Head of Corporate Development
2016 - 2017
Led Corporate Development activities, including corporate/financing strategy, partnering, legal and operational alliances across manufacturing, research and development. Drove evaluation of financing options and executed on competitive reverse merger process culminating in signing of merger with Mirna in May 2017.
Chief Business Officer
2014 - 2016
Padlock Therapeutics was acquired by Bristol-Myers Squibb (BMS) in 2016. Padlock Therapeutics was a venture-funded biotech company focused on developing therapeutic inhibitors of a family of enzymes called protein-arginine deiminases (PADs).
2006 - 2014
VP Corporate Development
2013 - 2014
VP, Program Executive for Fampyra
2012 - 2013
Vice President, Business Development
2010 - 2012
Sr. Director, Head of Product and Commercial Development for Hemophilia
2008 - 2010
Sr. Director, Corporate Development
2006 - 2008
Head of Mergers and Acquisitions for Biogen Idec. Led M&A strategy/evaluations and interactions with investment bankers. Led acquisition of Syntonix in January 2007 and was instrumental in Biogen Idec sale process in Q4 2007.
1998 - 2006
Director, Business Development
1998 - 2006
1997 - 1998
Associate, Business Development
1997 - 1998